128 related articles for article (PubMed ID: 19228609)
1. ADAGIO-Lipids gives promises but faces the setbacks.
Taskinen MR
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
[No Abstract] [Full Text] [Related]
2. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
3. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
4. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
5. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
Banasch M; Goetze O; Schmidt WE; Meier JJ
Liver Int; 2007 Oct; 27(8):1152-5. PubMed ID: 17845546
[No Abstract] [Full Text] [Related]
6. Rimonabant, obesity and diabetes.
Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
[TBL] [Abstract][Full Text] [Related]
7. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
8. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
[No Abstract] [Full Text] [Related]
9. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Gadde KM; Allison DB
Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
[No Abstract] [Full Text] [Related]
10. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
11. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
12. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
13. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
14. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
[No Abstract] [Full Text] [Related]
15. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
16. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for obesity--promise and uncertainty.
Yanovski SZ
N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
[No Abstract] [Full Text] [Related]
18. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR
J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374
[TBL] [Abstract][Full Text] [Related]
19. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
20. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
[No Abstract] [Full Text] [Related]
[Next] [New Search]